Sara A Hurvitz

List of Publications by Year
in descending order

134	12,194	66315 42	28275 105
papers	citations	h-index	g-index

136	136	136	11397
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine, 2018, 379, 753-763.	13.9	1,472
2	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. New England Journal of Medicine, 2020, 382, 610-621.	13.9	1,143
3	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	13.9	789
4	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. New England Journal of Medicine, 2019, 381, 307-316.	13.9	656
5	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 904-915.	5.1	648
6	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	13.9	601
7	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 2022, 386, 1143-1154.	13.9	474
8	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 904-916.	5.1	427
9	RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4286-4293.	0.8	379
10	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With â‰¥ 2 HER2-Directed Regimens: Phase III NALA Trial. Journal of Clinical Oncology, 2020, 38, 3138-3149.	0.8	355
11	Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2013, 31, 1157-1163.	0.8	342
12	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 115-126.	5.1	333
13	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. Journal of Clinical Oncology, 2020, 38, 2610-2619.	0.8	331
14	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncology, The, 2015, 16, 816-829.	5.1	261
15	Cycling cancer persister cells arise from lineages with distinct programs. Nature, 2021, 596, 576-582.	13.7	236
16	Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab. Journal of Clinical Oncology, 2010, 28, 5110-5115.	0.8	203
17	MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Reports, 2016, 14, 1590-1601.	2.9	174
18	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Journal of Clinical Oncology, 2019, 37, 2206-2216.	0.8	152

#	Article	IF	Citations
19	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2â€“Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology, 2016, 34, 2115-2124.	0.8	141
20	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 357-366.	5.1	125
21	Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2â^' Breast Cancer. Clinical Cancer Research, 2020, 26, 566-580.	3.2	125
22	Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treatment Reviews, 2013, 39, 219-229.	3.4	120
23	Analysis of Fcî³ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients. Clinical Cancer Research, 2012, 18, 3478-3486.	3.2	106
24	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research, 2019, 25, 2717-2724.	3.2	102
25	Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. Clinical Cancer Research, 2014, 20, 3507-3520.	3.2	100
26	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2â^' Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, 2022, 28, 851-859.	3.2	90
27	Rational management of endocrine resistance in breast cancer. Cancer, 2008, 113, 2385-2397.	2.0	79
28	Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics, 2018, 17, 897-907.	1.9	77
29	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research, 2019, 25, 2975-2987.	3.2	76
30	Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Research, 2020, 22, 89.	2.2	74
31	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncology, The, 2011, 12, 369-376.	5.1	73
32	Triple-negative breast cancer. Current Opinion in Obstetrics and Gynecology, 2015, Publish Ahead of Print, 59-69.	0.9	71
33	Advances in Targeted Therapies for Triple-Negative Breast Cancer. Drugs, 2019, 79, 1217-1230.	4.9	71
34	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment, 2013, 141, 437-446.	1.1	70
35	Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2014, 6, 202-209.	1.4	63
36	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clinical Cancer Research, 2019, 25, 2433-2441.	3.2	62

#	Article	IF	Citations
37	Estrogen Receptor (ER)Î±-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression. Journal of Biological Chemistry, 2015, 290, 5566-5581.	1.6	61
38	Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist, 2020, 25, e439-e450.	1.9	61
39	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology, 2018, 36, 3126-3133.	0.8	52
40	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. European Journal of Cancer, 2018, 103, 147-154.	1.3	52
41	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 4870-4882.	3.2	49
42	In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Research and Treatment, 2015, 149, 669-680.	1.1	46
43	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast, 2015, 24, 182-190.	0.9	44
44	NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptorâ€“positive (HR+), human epidermal growth factor receptor 2â€“negative (HER2â€“) early breast cancer (EBC).. Journal of Clinical Oncology, 2019, 37, TPS597-TPS597.	0.8	44
45	Effect and Efficiency of an Embedded Palliative Care Nurse Practitioner in an Oncology Clinic. Journal of Oncology Practice, 2017, 13, e792-e799.	2.5	42
46	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nature Communications, 2020, 11, 5824.	5.8	42
47	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nature Cancer, 2021, 2, 400-413.	5.7	41
48	Targeted Therapy for Premenopausal Women with HR+, HER2â^' Advanced Breast Cancer: Focus on Special Considerations and Latest Advances. Clinical Cancer Research, 2018, 24, 5206-5218.	3.2	40
49	nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treatment Reviews, 2014, 40, 614-625.	3.4	39
50	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist, 2020, 25, e214-e222.	1.9	39
51	Current status of therapeutic vaccines for non-Hodgkin??s lymphoma. Current Opinion in Oncology, 2005, 17, 432-440.	1.1	34
52	Afatinib in the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1039-1047.	1.9	33
53	Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. , 2020, 8, e000342.		32
54	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).. Journal of Clinical Oncology, 2016, 34, 500-500.	0.8	32

#	Article	IF	Citations
55	Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Annals of Translational Medicine, 2014, 2, 122.	0.7	32
56	Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer. Cancer, 2019, 125, 633-641.	2.0	31
57	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. Oncologist, 2021, 26, e1327-e1338.	1.9	31
58	Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 142, 603-609.	1.1	30
59	Use of a Shared Mental Model by a Team Composed of Oncology, Palliative Care, and Supportive Care Clinicians to Facilitate Shared Decision Making in a Patient With Advanced Cancer. Journal of Oncology Practice, 2016, 12, 1039-1045.	2.5	27
60	Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880733.	1.4	27
61	A careful reassessment of anthracycline use in curable breast cancer. Npj Breast Cancer, 2021, 7, 134.	2.3	25
62	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancerâ€”phase 3 ASCENT study subanalysis. Npj Breast Cancer, 2022, 8, .	2.3	25
63	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physicianâ€™s Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectrum, 2020, 4, pkz085.	1.4	24
64	The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Therapeutic Advances in Medical Oncology, 2012, 4, 235-245.	1.4	23
65	Whatâ€™s positive about â€˜triple-negativeâ€™ breast cancer?. Future Oncology, 2009, 5, 1015-1025.	1.1	22
66	The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2â€“positive metastatic breast cancer. BMC Cancer, 2014, 14, 307.	1.1	21
67	Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. Cancer Treatment Reviews, 2014, 40, 320-326.	3.4	21
68	Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmacogenomics and Personalized Medicine, 2014, 7, 329.	0.4	19
69	Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Breast Cancer Research, 2017, 19, 47.	2.2	19
70	Harnessing the immune system in the battle against breast cancer. Drugs in Context, 2018, 7, 1-21.	1.0	19
71	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clinical Cancer Research, 2020, 26, 1105-1113.	3.2	19
72	Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Research and Treatment, 2020, 181, 233-248.	1.1	19

#	Article	IF	Citations
73	Optimal Management of Early and Advanced HER2 Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 76-92.	1.8	17
74	Clinical features of pseudocirrhosis in metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 177, 409-417.	1.1	16
75	Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.. Journal of Clinical Oncology, 2021, 39, 1038-1038.	0.8	16
76	Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint. Cancer Treatment Reviews, 2011, 37, 495-504.	3.4	15
77	PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. Journal of Neuro-Oncology, 2014, 117, 7-13.	1.4	15
78	Genomic Profiling of Premenopausal HR+ and HER2â€“ Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO Precision Oncology, 2021, 5, 1408-1420.	1.5	15
79	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 127-139.	1.1	15
80	Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. European Journal of Cancer, 2018, 104, 160-168.	1.3	14
81	Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer. Clinical Advances in Hematology and Oncology, 2016, 14, 520-30.	0.3	13
82	TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS623-TPS623.	0.8	13
83	A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01). Clinical Breast Cancer, 2010, 10, 307-312.	1.1	12
84	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Targeted Oncology, 2019, 14, 647-656.	1.7	12
85	Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancerâ€"Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers, 2019, 11, 1987.	1.7	12
86	Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clinical Cancer Research, 2022, 28, 1383-1390.	3.2	12
87	LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment.. Journal of Clinical Oncology, 2012, 30, TPS649-TPS649.	0.8	11
88	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. Annals of Oncology, 2022, 33, 234-238.	0.6	11
89	Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic. Annals of Surgical Oncology, 2016, 23, 634-641.	0.7	10
90	Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. PLoS ONE, 2021, 16, e0251163.	1.1	9

#	Article	IF	Citations
91	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. Journal of Clinical Oncology, 2022, 40, 1000-1000.	0.8	9
92	Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.. Journal of Clinical Oncology, 2022, 40, 1028-1028.	0.8	9
93	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. Journal of Clinical Oncology, 2020, 38, 1005-1005.	0.8	8
94	The debate over post-mastectomy radiotherapy should continue. Nature Reviews Clinical Oncology, 2015, 12, 567-568.	12.5	7
95	Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.. Journal of Clinical Oncology, 2019, 37, 548-548.	0.8	7
96	Sacituzumab govitecan (SG) versus treatment of physicianâ€™s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.. Journal of Clinical Oncology, 2022, 40, 1071-1071.	0.8	7
97	Dose intensification of chemotherapy for early breast cancer in the age of de-escalation. Lancet, The, 2019, 393, 1390-1392.	6.3	6
98	Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. Clinical Breast Cancer, 2018, 18, e205-e218.	1.1	5
99	Is the duration of adjuvant trastuzumab debate still clinically relevant?. Lancet, The, 2019, 393, 2565-2567.	6.3	5
100	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Research and Treatment, 2021, 188, 179-190.	1.1	5
101	First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer.. Journal of Clinical Oncology, 2021, 39, e13043-e13043.	0.8	5
102	Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review. Breast, 2021, 57, 95-103.	0.9	5
103	Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?. Clinical Breast Cancer, 2021, 21, 526-531.	1.1	5
104	Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.. Blood, 2006, 108, 2729-2729.	0.6	5
105	Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. Journal of Clinical Oncology, 2019, 37, 500-500.	0.8	5
106	Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 1854-1862.	3.2	5
107	Oncotype DX Recurrence Score in premenopausal women. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210810.	1.4	4
108	Anthracycline Use inERBB2-Positive Breast Cancer. JAMA Oncology, 2021, 7, 975.	3.4	3

#	Article	IF	Citations
109	A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity. Oncotarget, 2016, 7, 78577-78590.	0.8	3
110	SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS1104-TPS1104.	0.8	3
111	Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncology Practice, 2022, 18, e484-e494.	1.4	3
112	NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer. Systematic Reviews, 2015, 4, 133.	2.5	2
113	Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer. Breast Cancer Research and Treatment, 2021, 190, 357-372.	1.1	2
114	How are quality of life and work productivity associated with living longer with HER2+ metastatic breast cancer?. Journal of Clinical Oncology, 2017, 35, 215-215.	0.8	2
115	Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.. Journal of Clinical Oncology, 2018, 36, 1005-1005.	0.8	2
116	Dissemination of breast cancer knowledge and expertise from NCI-CCC tumor boards with community oncologists.. Journal of Clinical Oncology, 2018, 36, e18575-e18575.	0.8	2
117	Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210855.	1.4	2
118	Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-16-15-P5-16-15.	0.4	2
119	Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. Breast Cancer Research and Treatment, 2017, 166, 145-156.	1.1	1
120	HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer. Lancet Oncology, The, 2020, 21, 1392-1393.	5.1	1
121	Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and â‰¥2 prior HER2-directed regimens. , 2021, , .		1
122	Finding the Sweet Spot in the Management of Early HER2+ Breast Cancer. JCO Oncology Practice, 2021, 17, 331-333.	1.4	1
123	Validation of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women receiving treatment for metastatic breast cancer.. Journal of Clinical Oncology, 2012, 30, 9144-9144.	0.8	1
124	What Does the Future Hold for PI3K/AKT/mTOR Inhibitors in Breast Cancer?. The Journal of Oncopathology, 2014, 1, 73-81.	0.1	1
125	New directions in the neoadjuvant treatment of HER2+ breast cancer. Breast Cancer Management, 2015, 4, 223-234.	0.2	0
126	Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease. Journal of Clinical Oncology, 2019, 37, 1044-1046.	0.8	0

#	Article	IF	Citations
127	Improvement of Idiotype Vaccine Efficacy Using a Sulfhydryl-Based Carrier Protein Conjugation Method: Results in Multiple Murine Lymphoma Models.. Blood, 2005, 106, 1481-1481.	0.6	0
128	Superior T Cell and Humoral Immunity Generated Against B Cell Lymphomas Using a Sulfhydryl-Based Idiotype Carrier Protein Conjugation Method.. Blood, 2006, 108, 232-232.	0.6	0
129	Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, TPS725-TPS725.	0.8	0
130	Implementation and dissemination of a shared mental model of palliative oncology.. Journal of Clinical Oncology, 2019, 37, 58-58.	0.8	0
131	Oncology team perception and patient experience discordances in triple-negative breast cancer (TNBC) care.. Journal of Clinical Oncology, 2020, 38, e19176-e19176.	0.8	0
132	Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-16-01-P5-16-01.	0.4	0
133	Abstract P5-17-12: First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients. Cancer Research, 2022, 82, P5-17-12-P5-17-12.	0.4	0
134	Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.. Journal of Clinical Oncology, 2022, 40, TPS1112-TPS1112.	0.8	0